Diagnosis and treatment of fetal and pediatric age patients (0-12 years) with Wolff-Parkinson-White syndrome and atrioventricular accessory pathways.
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
23
8
2023
pubmed:
6
7
2023
entrez:
6
7
2023
Statut:
ppublish
Résumé
Overt or concealed accessory pathways are the anatomic substrates of ventricular preexcitation (VP), Wolff-Parkinson-White syndrome (WPW) and paroxysmal supraventricular tachycardia (PSVT). These arrhythmias are commonly observed in pediatric age. PSVT may occur at any age, from fetus to adulthood, and its symptoms range from none to syncope or heart failure. VP too can range from no symptoms to sudden cardiac death. Therefore, these arrhythmias frequently need risk stratification, electrophysiologic study, drug or ablation treatment. In this review of the literature, recommendations are given for diagnosis and treatment of fetal and pediatric age (≤12 years) WPW, VP, PSVT, and criteria for sport participation.
Identifiants
pubmed: 37409656
doi: 10.2459/JCM.0000000000001484
pii: 01244665-202309000-00001
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
589-601Informations de copyright
Copyright © 2023 Italian Federation of Cardiology - I.F.C. All rights reserved.
Références
Cohen MI, Triedman JK, Cannon BC, Davis AM, Drago F, Janousek J, et al. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff–Parkinson–White (WPW, ventricular preexcitation) electrocardiographic pattern. Heart Rhythm 2012; 9:1006–1024.
Gillette PC, Freed D, McNamara DG. A proposed autosomal dominant method of inheritance of the Wolff–Parkinson–White syndrome and supraventricular tachycardia. J Pediatr 1978; 93:257–258.
Chia BL, Yew FC, Chay SO, Tan AT. Familial Wolff–Parkinson–White syndrome. J Electrocardiol 1982; 15:195–198.
MacRae CA, Ghaisas N, Kass S, Donnelly S, Basson CT, Watkins HC, et al. Familial hypertrophic cardiomyopathy with Wolff–Parkinson–White syndrome maps to a locus on chromosome 7q3. J Clin Invest 1995; 96:1216–1220.
Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, et al. Identification of a gene responsible for familial Wolff–Parkinson–White syndrome. N Engl J Med 2001; 344:1823–1831.
Gollob MH, Green MS, Tang AS, Roberts R. PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol 2002; 17:229–234.
Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005; 352:362–372.
O’Callaghan FJ, Clarke AC, Joffe H, Keeton B, Martin R, Salmon A, et al. Tuberous sclerosis complex and Wolff–Parkinson–White syndrome. Arch Dis Child 1998; 78:159–162.
Yuan SM. Fetal arrhythmias. Surveillance and management. Hellenic J Cardiol 2019; 60:72–81.
Donofrio MT, Moon-Grady AJ, Hornberger LK, Keeton B, Martin R, Salmon A, et al. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation 2014; 129:2183–2242.
Zoeller BB. Treatment of fetal supraventricular tachycardia. Curr Treat Options Cardiovasc Med 2017; 19:7.
Hinkle KA, Peyvandi S, Stiver C, Killen SAS, Weng HY, Etheridge SP, et al. Postnatal outcomes of fetal supraventricular tachycardia: a multicenter study. Pediatr Cardiol 2017; 38:1317–1323.
Kleinman CS, Nehgme RA. Cardiac arrhythmias in the human fetus. Pediatr Cardiol 2004; 25:234–251.
Wacker-Gussmann A, Strasburger JF, Cuneo BF, Wakai RT. Diagnosis and treatment of fetal arrhythmia. Am J Perinatol 2014; 31:617–628.
D’Alto M, Russo MG, Paladini D, Di Salvo G, Romeo E, Ricci C, et al. The challenge of fetal dysrhythmias: echocardiographic diagnosis and clinical management. J Cardiovasc Med (Hagerstown) 2008; 9:153–160.
El Hamriti M, Braun M, Molatta S, Imnadze G, Khalaph M, Lucas P, et al. EASY-WPW: a novel ECG-algorithm for easy and reliable localization of manifest accessory pathways in children and adults. Europace 2023; 25:600–609.
Baek SM, Song MK, Uhm JS, Kim GB, Bae EJ. New algorithm for accessory pathway localization focused on screening septal pathways in pediatric patients with Wolff–Parkinson–White syndrome. Heart Rhythm 2020; 17:2172–2179.
Leonelli FM, De Ponti R, Bagliani G. Clinical approach to symptomatic and asymptomatic patients with ventricular preexcitation. Card Electrophysiol Clin 2020; 12:527–539.
Mah DY, Sherwin ED, Alexander ME, Cecchin F, Abrams DJ, Walsh EP, et al. The electrophysiological characteristics of accessory pathways in pediatric patients with intermittent preexcitation. PACE 2013; 36:1117–1122.
Escudero CA, Ceresnak SR, Collins KK, Pass RH, Aziz PF, Blaufox AD, et al. Loss of ventricular preexcitation during noninvasive testing does not exclude high-risk accessory pathways: a multicenter study of WPW in children. Heart Rhythm 2020; 17:1729–1737.
Etheridge SP, Escudero CA, Blaufox AD, Law IH, Dechert-Crooks BE, Stephenson EA, et al. Life-threatening event risk in children with Wolff–Parkinson–White syndrome: a multicenter international study. JACC Clin Electrophysiol 2018; 4:433–444.
Khaznadar R, Chandler SF, Chaouki AS, Tsao S, Webster G. Noninvasive risk stratification in pediatric ventricular preexcitation. Pediatr Cardiol 2020; 41:709–715.
Zeppenfeld K, Tfelt-Hansen J, de Riva M, Gregers Winkel B, Behr ER, Blom NA, et al. ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022; 43:3997–4126.
Munger TM, Packer DL, Hammill SC, Feldman BJ, Bailey KR, Ballard DJ, et al. A population study of the natural history of Wolff–Parkinson–White syndrome in Olmsted County, Minnesota, 1953–1989. Circulation 1993; 87:866–873.
Obeyesekere MN, Leong-Sit P, Massel D, Manlucu J, Modi S, Krahn AD, et al. Risk of arrhythmia and sudden death in patients with asymptomatic preexcitation: a meta-analysis. Circulation 2012; 125:2308–2315.
Cain N, Irving C, Webber S, Beerman L, Arora G. Natural history of Wolff–Parkinson–White syndrome diagnosed in childhood. Am J Cardiol 2013; 112:961–965.
Montoya PT, Brugada P, Smeets J, Talajic M, Della Bella P, Lezaun R, et al. Ventricular fibrillation in the Wolff–Parkinson–White syndrome. Eur Heart J 1991; 12:144–150.
Pappone C, Vicedomini G, Manguso F, Saviano M, Baldi M, Pappone A, et al. Wolff–Parkinson–White syndrome in the era of catheter ablation: insights from a registry study of 2169 patients. Circulation 2014; 130:811–819.
Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States. Circulation 2009; 119:1085–1092.
Centurión OA, Shimizu A, Isomoto S, Konoe A. Mechanisms for the genesis of paroxysmal atrial fibrillation in the Wolff–Parkinson–White syndrome: intrinsic atrial muscle vulnerability vs. electrophysiological properties of the accessory pathway. Europace 2008; 10:294–302.
Di Mambro C, Russo MS, Righi D, Palmieri R, Silvetti MS, Gimigliano F, et al. Ventricular preexcitation: symptomatic and asymptomatic children have the same potential risk of sudden cardiac death. Europace 2015; 17:617–621.
Di Mambro C, Drago F, Milioni M, Russo MS, Righi D, Placidi S, et al. Sports eligibility after risk assessment and treatment in children with asymptomatic ventricular preexcitation. Sports Med 2016; 46:1183–1190.
Brembilla-Perrot B, Sellal JM, Olivier A, Villemin T, Moulin-Zinsch A, Beurrier D, et al. Evolution of clinical and electrophysiological data in children with a preexcitation syndrome. PACE 2016; 39:951–958.
Brembilla-Perrot B, Vincent J, Olivier A, Bozec E, Girerd N, Sellal JM. Does the age of evaluation change the long-term follow-up of untreated preexcitation syndrome? J Electrocardiol 2018; 51:792–797.
Protocolli cardiologici per il giudizio di idoneità allo sport agonistico. Comitato Organizzativo Cardiologico per l’Idoneità allo Sport COCIS 2017. ANCE – ANMCO – FMSI – SIC – SIC Sport. Casa Editrice Scientifica Internazionale, Roma; 2017.
O’Leary ET, Alexander ME, Bezzerides VJ, Drogosz M, Economy KE, Friedman KG, et al. Low mortality in fetal supraventricular tachycardia: outcomes in a 30 year single-institution experience. J Cardiovasc Electrophysiol 2020; 31:1105–1113.
Ekiz A, Kaya B, Bornaun H, Acar DK, Avci ME, Bestel A, et al. Flecainide as first-line treatment for fetal supraventricular tachycardia. J Matern Fetal Neonatal Med 2018; 31:407–412.
Shah A, Moon-Grady AJ, Bhogal N, Collins KK, Tacy T, Brook M, et al. Effectiveness of sotalol as first-line therapy for fetal supraventricular tachyarrhythmias. Am J Cardiol 2012; 109:1614–1618.
Strasburger JF, Cuneo BF, Michon MM, Gotteiner NL, Deal BJ, McGregor SN, et al. Amiodarone therapy for drug-refractory fetal tachycardia. Circulation 2004; 109:375–379.
Miyoshi T, Maeno Y, Hamasaki T, Inamura N, Yasukochi S, Kawataki M, et al. Antenatal therapy for fetal supraventricular tachyarrhythmias: multicenter trial. J Am Coll Cardiol 2019; 74:874–885.
Romeo E, D’Alto M, Russo MG, Sarubbi B, Cardaropoli D, Paladini D, et al. Fetal Supraventricular tachycardia diagnosed and treated at twenty-four weeks of gestation and after birth: a case report. Ital Heart J 2004; 5:777–780.
Page RL, Joglar JA, Caldwell M, Calkins H, Conti JB, Deal BJ, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2016; 13:e92–e135.
Chu PY, Hill KD, Clark RH, Brian Smith P, Hornik CP. Treatment of supraventricular tachycardia in infants: analysis of a large multicenter database. Early Hum Dev 2015; 91:345–350.
Capponi G, Belli G, Giovannini M, Remaschi G, Brambilla A, Vannuccini F, et al. Supraventricular tachycardias in the first year of life: what is the best pharmacological treatment? 24 years of experience in a single centre. BMC Cardiovasc Disord 2021; 21:137.
Drago F, Silvetti MS, De Santis A, Marcora S, Fazio G, Anaclerio S, et al. Paroxysmal reciprocating supraventricular tachycardia in infants: electrophysiologically guided medical treatment and long-term evolution of the re-entry circuit. Europace 2008; 10:629–635.
Vignati G, Balla E, Mauri L, Lunati M, Figini A. Clinical and electrophysiologic evolution of the Wolf–Parkinson–White syndrome in children: impact on approaches to management. Cardiol Young 2000; 10:367–375.
Ferlini M, Colli AM, Bonanomi C, Salvini L, Galli MA, Salice P, et al. Flecainide as first-line treatment for supraventricular tachycardia in newborns. J Cardiovasc Med 2009; 10:372–375.
Hill AC, Silka MJ, Bar-Cohen Y. A comparison of oral fecainide and amiodarone for the treatment of recurrent supraventricular tachycardia in children. PACE Pacing Clin Electrophysiol 2019; 42:670–677.
Piersigilli F, Auriti C, Silvetti MS, Marrocco G, Drago F, Seganti G. Profuse oral secretions after propafenone administration in neonates. J Pediatr 2010; 157:856–857.
Silvetti MS, Drago F, Bevilacqua M, Ragonese P. Amiodarone-induced torsade de pointes in a child with dilated cardiomyopathy. Ital Heart J 2001; 2:231–236.
Brugada J, Blom N, Sarquella-Brugada G, Blomstrom-Lundqvist C, Deanfield J, Janousek J, et al. Pharmacological and nonpharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace 2013; 15:1337–1382.
Saul JP, Kanter RJ, Abrams D, Asirvatham S, Bar-Cohen Y, Blaufox AD, et al. PACES/HRS expert consensus statement on the use of catheter ablation in children and patients with congenital heart disease: developed in partnership with the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Heart Rhythm 2016; 13:e251–e289.
Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomström-Lundqvist C, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020; 41:655–720.
Stabile G, Bertaglia E, Guerra F, Palmisano P, Zoni Berisso M, Soldati E, et al. Associazione Italiana di Aritmologia e Cardiostimolazione (AIAC). Organization and procedures in contemporary catheter ablation centres: data from the 2018 Italian Catheter Ablation Registry. J Cardiovasc Med (Hagerstown) 2021; 22:631–636.
Saul JP, Hulse JE, Papagiannis J, Van Praagh R, Walsh EP. Late enlargement of radiofrequency lesions in infant lambs: implications for ablation procedures in small children. Circulation 1994; 90:492–499.
Blaufox AD, Saul JP. Acute coronary artery stenosis during slow pathway ablation for atrioventricular nodal reentrant tachycardia in a child. J Cardiovasc Electrophysiol 2004; 15:97–100.
Krause U, Abreu da Cunha FD, Backhoff D, Jacobshagen C, Klehs S, Schneider HE, et al. Effects of triple cryoenergy application on lesion formation and coronary arteries in the developing myocardium. Pediatr Cardiol 2017; 38:663–668.
Drago F, De Santis A, Grutter G, Silvetti MS. Transvenous cryothermal catheter ablation of re-entry circuit located near the atrioventricular junction in pediatric patients: efficacy, safety and midterm follow-up. J Am Coll Cardiol 2005; 45:1096–1103.
Drago F, Silvetti MS, De Santis A, Grutter G, Andrew P. Lengthier cryoablation and a bonus cryoapplication is associated with improved efficacy for cryo catheter ablation of supraventricular tachycardias in children. J Interv Card Electrophysiol 2006; 16:191–198.
Drago F, Russo MS, Silvetti MS, De Santis A, Naso Onofrio MT. Time to effect during cryomapping: a parameter related to the long-term success of accessory pathways cryoablation in children. Europace 2009; 11:630–634.
Silvetti MS. The day after the new little ice age… (or the chronic outcome of pediatric slow pathway cryoablation). Heart Rhythm 2022; 19:270–271.
Dagres N, Chao TF, Fenelon G, Aguinaga L, Benhayon D, Benjamin EJ, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? Heart Rhythm 2018; 15:e37–e60.
Krause U, Paul T, Bella PD, Gulletta S, Gebauer RA, Paech C, et al. Pediatric catheter ablation at the beginning of the 21st century: results from the European Multicenter Pediatric Catheter Ablation Registry ‘EUROPA’. Europace 2021; 23:431–440.
Kugler JD, Danford DA, Houston KA, Felix G. Pediatric Radiofrequency Ablation Registry of the Pediatric Radiofrequency Ablation Registry of the Pediatric Electrophysiology Society. Pediatric radiofrequency catheter ablation registry success, fluoroscopy time, and complication rate for supraventricular tachycardia: comparison of early and recent eras. J Cardiovasc Electrophysiol 2002; 13:336–341.
Drago F, Grifoni G, Remoli R, Russo MS, Righi D, Pazzano V, et al. Radiofrequency catheter ablation of left-sided accessory pathways in children using a new fluoroscopy integrated 3D-mapping system. Europace 2017; 19:1198–1203.
Smith G, Clark JM. Elimination of fluoroscopy use in a pediatric electrophysiology laboratory utilizing three-dimensional mapping. Pacing Clin Electrophysiol 2007; 30:510–518.
Russo MS, Drago F, Silvetti MS, Righi D, Di Mambro C, Placidi S, et al. Comparison of cryoablation with 3D mapping versus conventional mapping for the treatment of atrioventricular re-entrant tachycardia and right-sided paraseptal accessory pathways. Cardiol Young 2016; 26:931–940.
Drago F, Tamborrino PP, Pazzano V, Di Mambro C, Silvetti MS. 3D transvenous radiofrequency ablation of manifest epicardial posterior-septal accessory pathways in children: can technology innovations improve the outcome? Cardiol Young 2021; 29:1–6.
Drago F, Silvetti MS, Di Pino A, Grutter G, Bevilacqua M, Leibovich S. Exclusion of fluoroscopy during ablation treatment of right accessory pathway in children. J Cardiovasc Electrophysiol 2002; 13:778–782.
Mah DY, Miyake CY, Sherwin ED, Walsh A, Anderson MJ, Western K, et al. The use of an integrated electroanatomic mapping system and intracardiac echocardiography to reduce radiation exposure in children and young adults undergoing ablation of supraventricular tachycardia. Europace 2014; 16:277–283.
Tuzcu V. Significant reduction of fluoroscopy in pediatric catheter ablation procedures: long-term experience from a single center. Pacing Clin Electrophysiol 2012; 35:1067–1073.
Scaglione M, Ebrille E, Caponi D, Siboldi A, Bertero G, Di Donna P, et al. Zerofluoroscopy ablation of accessory pathways in children and adolescents: CARTO3 electroanatomic mapping combined with RF and cryoenergy. Pacing Clin Electrophysiol 2015; 38:675–681.
Manolis AS, Wang PJ, Estes NA. Radiofrequency ablation of left-sided accessory pathways: transaortic versus transseptal approach. Am Heart J 1994; 128:896–902.
Russo V, Nesti M, Brunacci M, Tola G, Santobuono VE, Dendramis G, et al. Cardiac electrophysiology and pacing educational and training needs among early-career cardiologists: national survey of the Young Committee of the Italian Association of Arrhythmology and Cardiac Pacing. J Cardiovasc Med (Hagerstown) 2021; 22:744–750.
Schaffer MS, Gow RM, Moak JP, Saul JP. Mortality following radiofrequency catheter ablation (from the Pediatric Radiofrequency Ablation Registry). Participating Members of the Pediatric Electrophysiology Society. Am J Cardiol 2000; 86:639–643.
Van Hare GF, Javitz H, Carmelli D, Saul JP, Tanel RE, Fischbach PS, et al. Prospective assessment after pediatric cardiac ablation: demographics, medical profiles, and initial outcomes. J Cardiovasc Electrophysiol 2004; 15:759–770.
Kubuš P, Vít P, Gebauer RA, et al. Long-term results of pediatric radiofrequency catheter ablation: a population-based study. Europace 2014; 16:1808–1813.
Drago F, Righi D, Placidi S, Russo MS, Di Mambro C, Silvetti MS, et al. Cryoablation of right-sided accessory pathways in children: report of efficacy and safety after 10-year experience and follow-up. Europace 2013; 15:1651–1656.
Spar DS, Silver ES, Hordof AJ, Torres A, Liberman L. Coronary artery spasm during radiofrequency ablation of a left lateral accessory pathway. Pediatric Cardiol 2010; 31:724–727.
Yeo KK, Davenport J, Raff G, Laird JR. Life-threatening coronary sinus thrombosis following catheter ablation: case report and review of literature. Cardiovas Revasc Med 2010; 11:262.e1–262.e5.
Hanslik A, Mujagic A, Mlczoch E, Gössinger H, Gwechenberger M, Richter B, et al. Radiofrequency catheter ablation can be performed with high success rates and very low complication rates in children and adolescents. Acta Pediatrica 2014; 103:e188–e193.
Emmel M, Balaji S, Sreeram N. Ventricular preexcitation associated with dilated cardiomyopathy: a causal relationship? Cardiol Young 2004; 14:594–599.
Tomaske M, Janousek J, Razek V, Gebauer RA, Tomek V, Hindricks G, et al. Adverse effects of Wolff–Parkinson–White syndrome with right septal or posteroseptal accessory pathways on cardiac function. Europace 2008; 10:181–189.
Park HE, Chang SA, Kim JH, Oh IY, Choi EK, Oh S. Left ventricular dyssynchrony in preexcitation syndrome: effect of accessory pathway location and reversibility after ablation therapy. Heart Vessels 2013; 28:199–207.
Abadir S, Fournier A, Dubuc M, Sarquella-Brugada G, Garceau P, Khairy P. Ventricular dyssynchrony and function improve following catheter ablation of nonseptal accessory pathways in children. Biomed Res Int 2013; 2013:158621.
Dai CC, Guo BJ, Li WX, Xiao YY, Jin M, Han L, et al. Dyssynchronous ventricular contraction in Wolff–Parkinson–White syndrome: a risk factor for the development of dilated cardiomyopathy. Eur J Pediatr 2013; 172:1491–1500.
Fukunaga H, Akimoto K, Furukawa T, Takahashi K, Kishiro M, Shimizu T, et al. Improvement in nontachycardia-induced cardiac failure after radiofrequency catheter ablation in a child with a right-sided accessory pathway. Heart Vessels 2013; 28:802–807.
Decreti legge Italiani: articolo 7, comma 11, del decreto-legge 13 settembre 2012,n.158, convertito, con modifìcazioni, dalla legge 8 novembre 2012,n.189; decreto ministeriale 24 aprile 2013, pubblicato nella Gazzetta Ufficiale 20 luglio 2013; articolo 42-bis, comma 2, del decreto-legge 21 giugno 2013, n. 69, convertito dalla legge 9 agosto 2013,n. 98, e successive modificazioni; decreto ministeriale 8 agosto 2014, pubblicato nella Gazzetta Ufficiale 21 giugno 2013,n. 144; decreto interministeriale dei ministeri di Salute e Sport 28/02/2018.
Goudevenos JA, Katsouras CS, Graekas G, Argiri O, Giogiakas V, Sideris D. Ventricular preexcitation in the general population: a study on the mode of presentation and clinical course. Heart 2000; 83:29–34.
Pappone C, Manguso F, Santinelli R, Vicedomini G, Sala S, Paglino G, et al. Radiofrequency ablation in children with asymptomatic Wolff–Parkinson–White syndrome. N Engl J Med 2004; 351:1197–1205.
Heidbuchel H, Adami PE, Antz M, Braunschweig F, Delise P, Scherr D, et al. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions: Part 1: Supraventricular arrhythmias. A position statement of the Section of Sports Cardiology and Exercise from the European Association of Preventive Cardiology (EAPC) and the European Heart Rhythm Association (EHRA), both associations of the European Society of Cardiology. Eur J Prev Cardiol 2021; 28:1539–1551.
Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines on sports cardiology and exercice in patients witch cardiovascular disease. Eur Heart J 2021; 42:17–96.